LOS ANGELES - INmune Bio , Inc. (NASDAQ:INMB), a clinical-stage biotech company valued at $175 million, has announced the treatment of the first patient in the Phase II segment of its ongoing clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback